Tseretopoulou Xanthippi, Ali Salma R, Bryce Jillian, Amin Nadia, Atapattu Navoda, Bachega Tania A S S, Baronio Federico, Ortolano Rita, Birkebaek Niels H, Bonfig Walter, Cools Martine, Davies Justin H, Thomas Tessy, de Vries Liat, Elsedfy Heba, Amr Nermine H, Flueck Christa E, Globa Evgenia, Guran Tulay, Yavas-Abali Zehra, Guven Ayla, Hannema Sabine E, Iotova Violeta, Konrad Daniel, Lenherr-Taube Nina, Krone Nils P, Leka-Emiri Sofia, Vlachopapadopoulou Elpis, Lichiardopol Corina, Marginean Otilia, Markosyan Renata, Neumann Uta, Niedziela Marek, Banaszak-Ziemska Magdalena, Phan-Hug Franziska, Poyrazoglu Sukran, Probst-Scheidegger Ursina, Randell Tabitha, Russo Gianni, Salerno Mariacarolina, Seneviratne Sumudu, Shnorhavorian Margarett, Thankamony Ajay, Tadokoro-Curraro Rieko, van den Akker Erica, van Eck Judith, Vieites Ana, Wasniewska Malgorzata, Ahmed S Faisal
Developmental Endocrinology Research Group, School of Medicine, Dentistry & Nursing, University of Glasgow, Glasgow G51 4TF, UK.
Office for Rare Conditions, Royal Hospital for Children & Queen Elizabeth University Hospital, Glasgow G51 4TF, UK.
J Endocr Soc. 2024 Aug 20;8(10):bvae145. doi: 10.1210/jendso/bvae145. eCollection 2024 Aug 27.
It is unclear whether targeted monitoring of acute adrenal insufficiency (AI) related adverse events (AE) such as sick day episodes (SDEs) and hospitalization rate in congenital adrenal hyperplasia (CAH) is associated with a change in the occurrence of these events.
Study temporal trends of AI related AE in the I-CAH Registry.
In 2022, data on the occurrence of AI-related AE in children aged <18 years with 21-hydroxylase deficiency CAH were compared to data collected in 2019.
In 2022, a total of 513 children from 38 centers in 21 countries with a median of 8 children (range 1-58) per center had 2470 visits evaluated over a 3-year period (2019-2022). The median SDE per patient year in 2022 was 0 (0-2.5) compared to 0.3 (0-6) in 2019 ( = .01). Despite adjustment for age, CAH phenotype and duration of study period, a difference in SDE rate was still apparent between the 2 cohorts. Of the 38 centers in the 2022 cohort, 21 had also participated in 2019 and a reduction in SDE rate was noted in 13 (62%), an increase was noted in 3 (14%), and in 5 (24%) the rate remained the same. Of the 474 SDEs reported in the 2022 cohort, 103 (22%) led to hospitalization compared to 299 of 1099 SDEs (27%) in the 2019 cohort ( = .02).
The I-CAH Registry can be used for targeted monitoring of important clinical benchmarks in CAH. However, changes in reported benchmarks need careful interpretation and longer-term monitoring.
目前尚不清楚对先天性肾上腺皮质增生症(CAH)中与急性肾上腺功能不全(AI)相关的不良事件(AE)进行针对性监测,如患病日发作(SDEs)和住院率,是否与这些事件的发生变化相关。
研究国际先天性肾上腺皮质增生症(I-CAH)注册中心中与AI相关的AE的时间趋势。
2022年,将21羟化酶缺乏型CAH的18岁以下儿童中与AI相关的AE的发生数据与2019年收集的数据进行比较。
2022年,来自21个国家38个中心的513名儿童,每个中心中位数为8名儿童(范围1 - 58名),在3年期间(2019 - 2022年)进行了2470次就诊评估。2022年每名患者每年的SDE中位数为0(0 - 2.5),而2019年为0.3(0 - 6)(P = 0.01)。尽管对年龄、CAH表型和研究期间进行了调整,但两个队列之间SDE率的差异仍然明显。在2022年队列的38个中心中,21个中心也参与了2019年的数据收集,其中13个中心(62%)的SDE率有所下降,3个中心(14%)有所上升,5个中心(24%)的率保持不变。在2022年队列报告的474次SDE中,103次(22%)导致住院,而2019年队列中1099次SDE中有299次(27%)导致住院(P = 0.02)。
I-CAH注册中心可用于对CAH的重要临床指标进行针对性监测。然而,报告指标的变化需要仔细解读并进行长期监测。